The uncertainty comes as a twice-yearly injectable could end HIV, as studies published last year showed that a drug by Gilead ...

A Bladen County woman appeared in court Thursday for the first time since being charged in the shooting death of her husband.

The first high-voltage transmission lines to cross into Michigan in 50 years cleared a key hurdle, teeing up a bevy eminent ...

We came across a bullish thesis on Gilead Sciences, Inc. on Dividend Talks’s Substack. In this article, we will summarize the ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

The $4 billion that the United States pledged for the global HIV response for 2025 disappeared virtually overnight in January ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...

In the latest close session, Gilead Sciences (GILD) was up +1.96% at $113.24. The stock outpaced the S&P 500's daily gain of 0.61%. On the other hand, the Dow registered a gain of 0.49%, and the ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Gilead Sciences Inc. closed 5.60% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...